Replies to post #177930 on Biotech Values

[tony111]

Just curious why are people interested in TGTX pipeline when there are already Idelalisib and Rutuximab on the market?

[jaybe]

I would be careful here with TGR-1202....the list of PI3K inhibitors with impressive activity at early stage only to disappoint in Phase 2, continues to grow. I know its early and 6 CLL patients is too few to judge, but 67% nodal response (down from 75% at ASH) does not compare favorably with single-agent idelalisib's 81%, not to mention ibrutinib's 100%.